Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Delisting risk
confidence 95%
filed 2026-07-22
The 6-K discloses that NetClass Technology received a Nasdaq deficiency notice on January 27, 2026 for failing to meet the minimum bid price requirement (below $1.00 for 30 consecutive business days), was given a 180-day compliance period until July 27, 2026, and subsequently regained compliance on July 21, 2026 following a 50-for-1 reverse stock split effective July 6, 2026. This is a material delisting risk event that was resolved through the reverse split, with Nasdaq confirming restoration of compliance on July 21, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-07-22
The filing discloses that GDEV Inc.'s public warrants (GDEVW) will expire on August 26, 2026, and upon expiration "will cease to trade and will be delisted from the Nasdaq Global Market." This is a notice of delisting of a security, which falls squarely within the delisting_risk category. While the warrants themselves are "currently out of the money," the material fact is the announced delisting of a publicly traded security from Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-22
Item 3.01
Following completion of the merger, NSA notified the NYSE of delisting. The NYSE suspended trading and filed Form 25 notifications removing NSA Common Shares, Series A Preferred Shares, and Series B Preferred Shares from listing, with NSA intending to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-22
Item 3.01
Northfield Common Stock was delisted from NASDAQ effective July 20, 2026, following completion of the merger with Columbia Financial. Columbia Financial intends to file Form 15 to deregister the stock and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-22
Item 3.01
Purple Innovation received a Nasdaq Panel decision on July 20, 2026 granting continued listing subject to strict conditions: the company must demonstrate a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days by July 31, 2026. The filing explicitly discloses delisting risk, noting "there can be no assurance that the Company will regain compliance" and that failure to do so would result in delisting from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-22
Item 3.01
SunPower received written notice from Nasdaq on July 21, 2026, that it failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days to regain compliance, with delisting as a consequence if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-22
The filing discloses a Nasdaq delisting notice under Item 3.01, indicating the Company failed to maintain the $1.00 minimum bid price requirement for 30 consecutive business days. While Item 1.01 addresses a standstill agreement with a convertible preferred investor, the material event is the delisting risk: the Company has until January 13, 2027 to regain compliance or face delisting. This is a terminal threat to the registrant's continued public trading status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-22
EX-99.1
Empro Group received a Staff Delisting Determination from Nasdaq on July 16, 2026, notifying the Company that Nasdaq has determined to delist its securities pursuant to Listing Rule IM-5101-4, citing both discretionary authority and the Company's delay in filing Form 20-F. The delisting is triggered by an SEC trading suspension order issued October 8, 2025, due to potential market manipulation. Trading suspension is scheduled for July 27, 2026, unless the Company appeals by July 23, 2026. This is a material delisting event that directly threatens the Company's continued listing and market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-22
Item 3.03
MicroVision announced a 1-for-15 reverse stock split explicitly "intended to increase the per-share trading price of MicroVision's common stock to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market." The press release states the reverse split "supports our continued Nasdaq listing," indicating the company faced delisting risk due to non-compliance with Nasdaq's minimum bid price requirement. This is a material disclosure of a listing compliance issue and the remedial action taken.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-22
The filing discloses a 1-for-40 reverse stock split explicitly undertaken to "enable the Company to manage continued compliance with The Nasdaq Capital Market Listing Rule 5550(a)(2)" — the minimum bid price rule. The press release states the split is "intended to increase the closing bid price of the Common Stock above $1.00 per share" to maintain Nasdaq listing compliance. This is a direct response to delisting risk triggered by failure to meet the minimum bid price requirement.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-22
Item 8.01
The Company received notification from OTC Markets Group that its common stock has been moved to the OTC Expert Market on an unsolicited quotes only basis. This represents a material downgrade in listing status and a significant delisting risk event, as movement to the OTC Expert Market typically indicates failure to meet continued listing standards and substantially reduces liquidity and investor access to the stock.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-21
EX-99.1
SOLAI Limited received a written notice from the NYSE on July 16, 2026, indicating that NYSE Regulation has determined to commence delisting proceedings for the Company's ADSs due to failure to maintain the minimum average global market capitalization of US$15,000,000 over a consecutive 30 trading day period. Trading was suspended on July 16, 2026, and the Company expects the ADSs to transition to OTC Markets. This is a clear delisting notice triggering the formal delisting process under NYSE Listed Company Manual Section 802.01B.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-21
Item 3.01
Cypherpunk Technologies received a Nasdaq deficiency notice on July 20, 2026, for failing to maintain the minimum $1.00 closing bid price required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The company has 180 days until January 19, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the registrant's continued listing status and investor confidence.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-21
Item 3.01
KORE notified the NYSE of the completion of the merger and requested suspension of trading and delisting of its common stock prior to market open on July 21, 2026. The company intends to file Form 15 to terminate its registration under Section 12(g) and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-21
Item 3.01
On July 17, 2026, Nuburu received a delisting notice from NYSE American because its common stock traded below $0.10, violating Section 1003(f)(v) of the NYSE American Company Guide. The company intends to appeal and implement a reverse stock split to regain compliance.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-07-21
The 6-K discloses a change in ticker symbol from YOOV to CIGL, effective July 21, 2026, on the Nasdaq Capital Market. While a ticker change alone is not necessarily a delisting event, it often signals a transfer of listing or a change in market tier (e.g., from Nasdaq Global Market to Nasdaq Capital Market, or vice versa). The disclosure of a "new ticker symbol" and the specific effective date suggest a material change in the registrant's listing status that would affect investor identification and trading of the security.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-21
The filing discloses that XTL Biopharmaceuticals has regained compliance with Nasdaq listing rules after a prior delisting threat, but remains subject to a one-year mandatory panel monitor with heightened consequences: any future breach of the Equity Rule will result in immediate delisting without cure rights. This is material because it signals ongoing listing vulnerability and constrains the company's operational flexibility during the monitoring period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-07-21
Item 3.01
Nasdaq Listing Qualifications Staff issued a determination letter on July 16, 2026 to delist the Company's common stock and warrants based on violations of Nasdaq Listing Rules 5205(e) and 5250(a)(1) related to disclosures regarding China Securities Regulatory Commission review status. The Company intends to appeal by July 23, 2026, but faces immediate delisting if the Panel reaches a unanimous decision against it.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-21
Item 5.03
Picard Medical implemented a 1-for-50 reverse stock split to support continued compliance with NYSE American continued listing standards. The reverse split was undertaken to address delisting risk and maintain the company's exchange listing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-21
EX-99.1
CN Energy Group received a written notification from Nasdaq dated July 15, 2026, stating it is no longer in compliance with Nasdaq Listing Rule 5550(a)(2) due to a closing bid price below $1.00 per share for 30 consecutive business days. Although the Company has a 180-day grace period (until January 12, 2027) to regain compliance, this is a material delisting risk disclosure that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 25%
filed 2026-07-21
EX-99.1
This exhibit announces CLINUVEL's commencement of trading on Nasdaq under ticker CUVL, with its existing over-the-counter ADR (CLVLY) upgrading from Level I to Level II. While the announcement describes a positive listing development, the risk statement explicitly notes "No final decision has been made" and "There is no guarantee that the uplisting will proceed." However, the primary substance is a successful listing event rather than a delisting risk, making this classification uncertain.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-20
EX-99.1
The exhibit discloses Above Food's engagement of counsel to appeal a Nasdaq delisting determination before the Nasdaq Listing and Hearing Review Council. The company explicitly states it "has requested review of Nasdaq's prior delisting determination" and references an outstanding Form 20-F filing obligation under Listing Rule 5250(c)(1). This is a material delisting-risk disclosure under Item 3.01 equivalent, as the company faces potential loss of listing due to non-compliance with filing requirements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-20
Item 3.01
The Nasdaq Hearings Panel issued a final delisting determination denying Sangamo's request to continue listing on The Nasdaq Capital Market due to failure to meet the minimum bid price requirement. The company's stock has been suspended from Nasdaq and is now trading on the OTCID Basic Market, with Nasdaq expected to file a Form 25 to delist and deregister the common stock.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-20
The filing discloses that Tenon Medical regained compliance with Nasdaq's Stockholders' Equity Rule (minimum $2.5 million) following a $4.2 million public offering on July 1, 2026. However, the company explicitly warns that "if the Company fails to evidence compliance upon filing its Quarterly Report on Form 10-Q for the period ending September 30, 2026, the Company may be subject to delisting." This is a material delisting risk disclosure under Item 8.01, as the company faces potential delisting if it cannot maintain the minimum equity threshold in its next quarterly report.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 99%
filed 2026-07-20
Item 3.01
The filing discloses a definitive delisting determination by the Nasdaq Hearings Panel on July 17, 2026, with trading suspension effective July 21, 2026, due to failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company's common stock will transfer from Nasdaq to the OTC Markets, materially reducing liquidity and trading price. This is a terminal delisting event, not merely a risk or notice of non-compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-20
Item 3.01
TEN Holdings received a deficiency letter from Nasdaq for failing to maintain the minimum $2,500,000 stockholders' equity required under Listing Rule 5550(b)(1), and while the company believes it has regained compliance through a $6.6 million registered direct offering, Nasdaq will continue monitoring and may subject the company to delisting if it fails to evidence compliance at its next periodic report. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-20
The filing discloses a Nasdaq delist determination letter dated July 15, 2026, notifying the Company that its securities will be delisted from The Nasdaq Global Market due to failure to maintain minimum Market Value of Listed Securities ($50 million) under Listing Rule 5450(b)(2)(A), with an additional basis being failure to meet the minimum 400 shareholder requirement. Trading suspension is scheduled for July 24, 2026, unless the Company appeals by July 22, 2026. This is a direct delisting notice under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-20
Item 8.01
The filing discloses a Nasdaq compliance violation under Listing Rule 5250(c)(1) for failure to timely file the Form 10-Q for the period ended March 31, 2026. Although the Company subsequently cured the violation by filing the Form 10-Q on July 16, 2026, the initial non-compliance notification and the cure represent a material delisting risk event. The disclosure of the violation itself—even though remedied—is material to investors as it signals potential operational or financial reporting challenges and demonstrates the Company came within reach of delisting consequences.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-20
Item 8.01
The Company disclosed receipt of a Nasdaq deficiency notification for failure to timely file its Form 10-Q, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). While the Company submitted a Compliance Plan and trading continues, the filing directly addresses a material delisting risk — the Company faces potential delisting if the Compliance Plan is rejected and it cannot regain compliance. This is a core delisting-risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-07-20
Item 3.01
SES AI received notice from the NYSE on July 17, 2026, that it failed to comply with Section 802.01C of the NYSE Listed Company Manual because the average closing price of its Class A common stock was below $1.00 over a consecutive 30 trading-day period. The company has a six-month cure period to regain compliance or face potential delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-17
EX-99.1
The press release discloses receipt of a Nasdaq Listing Qualifications Staff Determination Letter on July 14, 2026, notifying the Company that it failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The Company has been granted a 180-calendar-day compliance period (until January 11, 2027) to regain compliance, with potential for an additional 180-day period if certain conditions are met. This is a material delisting risk disclosure under Nasdaq Listing Rule 5810(b), which requires prompt disclosure of deficiency notifications.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-17
Item 8.01
Sadot Group disclosed that it failed to meet Nasdaq's minimum stockholders' equity requirement of $2,500,000 under Listing Rule 5550(b)(1), with explicit warning that failure to regain and maintain compliance could result in delisting, though management believes recent transactions have restored compliance to over $7,000,000.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-16
Item 3.01
Chart Industries notified the NYSE on July 16, 2026 of the completion of the merger and requested withdrawal of its listing, with plans to file Form 25 for delisting and Form 15 for deregistration.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-16
EX-99.1
The Company received a written notification from Nasdaq on July 14, 2026, stating non-compliance with Nasdaq Listing Rule 5250(c)(2) due to failure to file a Form 6-K containing interim financial statements for the six-month period ended December 31, 2025. The Company has 60 calendar days to submit a compliance plan, with potential extension to 180 days. The notice explicitly states "There can be no assurance that the Company's plan will be accepted or the Company will be able to regain compliance," and the Company will be listed as a non-compliant issuer. This is a clear delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-16
The 6-K discloses that the SEC suspended trading in the Company's securities from June 12–26, 2026, and that Nasdaq subsequently halted trading in the Company's Class A ordinary shares pending satisfaction of an information request. The Company submitted its response on July 10, 2026, but trading remains halted with "no assurance as to when, or whether, trading in the Company's Class A ordinary shares will resume." This is a material delisting risk — the registrant faces a continued listing threat and loss of trading access, which directly threatens investor liquidity and the registrant's capital-raising ability.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-16
EX-99.1
The press release discloses that Cellyan received a Nasdaq notification letter on July 14, 2026 granting an additional 180-day compliance grace period (until January 11, 2027) to regain compliance with the Nasdaq minimum $1.00 closing bid price requirement. The Company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days to avoid delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq and would materially affect a reasonable investor's assessment of the registrant's status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-16
EX-99.1
The press release discloses a Nasdaq notification that Ohmyhome has failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has been granted a 180-day compliance period (until January 11, 2027) to regain compliance, with potential for an additional 180-day extension if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01 — the Company faces potential delisting if it cannot restore its share price above $1.00 within the cure period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-16
EX-99.1
CBL International announced a 1-for-13 reverse share split "primarily to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of the minimum bid price per share." This disclosure reveals the company has fallen below Nasdaq's minimum bid price requirement and faces delisting risk absent this remedial action. The reverse split is a direct response to a continued listing rule violation, making this a material delisting-risk disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-16
Item 3.01 discloses that SRX Global has regained compliance with NYSE American listing standards after resolving deficiencies under Section 1003(a)(i) and (ii) of the Company Guide that were previously cited in an October 14, 2025 notice. The removal of the compliance indicator (".BC") and delisting risk is material to investors assessing the registrant's continued trading status and financial viability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-16
ZyVersa Therapeutics ceased trading on the OTCQB Venture Market and moved to the OTC Pink Limited Market effective July 16, 2026. This represents a downgrade in listing status and is a material transfer of listing that signals potential delisting risk or failure to maintain continued listing standards. The move from OTCQB to OTC Pink is a significant negative development for investor visibility and liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-16
Our Bond, Inc. received notification from Nasdaq on July 14, 2026 that it has failed to maintain compliance with three critical listing standards: minimum bid price of $1.00 per share, minimum market value of publicly held shares of $15 million, and minimum market value of listed securities of $50 million. The company has been granted 180 calendar days (until January 11, 2027) to regain compliance, and Nasdaq will publicly list the company as non-compliant on its website. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-16
EX-99.1
Pitanium Limited received a delisting determination letter from Nasdaq dated July 7, 2026, notifying the Company that Nasdaq Staff has determined to delist the Company's securities from Nasdaq pursuant to Listing Rule IM-5101-4. Trading suspension is scheduled for July 16, 2026, unless the Company appeals by July 14, 2026. This is a definitive delisting notice, not merely a risk or warning, making it a material event that directly affects the registrant's continued listing status and investor access to trading.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-16
Item 3.01
Cycurion received a Staff Determination Letter from Nasdaq on July 10, 2026, notifying the company of delisting due to failure to maintain the $1.00 minimum bid price for 31 consecutive business days. The company is ineligible for the customary 180-day compliance period due to a reverse stock split effected within the prior year, with trading suspension expected July 21, 2026 absent a timely hearing request.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-15
EX-99.1
Canaan received written notification from Nasdaq granting an additional 180-day compliance period (until January 11, 2027) to regain compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company previously received an initial notification on January 14, 2026, and has now exhausted its first compliance period. This disclosure directly addresses continued listing status and the risk of delisting if the Company fails to meet the minimum bid price threshold during the second compliance period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 8.01
Atlantic American Corporation disclosed that Nasdaq has notified it of non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Form 10-K and Form 10-Q. The company has been granted an extension until October 12, 2026 to regain compliance, with explicit warning that failure to do so will result in delisting notification from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01 (though filed under Item 8.01), materially threatening the continued listing of the company's common stock.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 3.01
SemiLEDs received a Nasdaq delisting notice on January 30, 2026 for failing to meet the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1). Although the company claims to have regained compliance as of May 31, 2026 with $3.1 million in equity, Nasdaq retains the right to delist if compliance is not evidenced at the next periodic report. This is a classic delisting-risk disclosure under Item 3.01, material to investors assessing the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 3.01
Following the merger completion, Nuvalent notified Nasdaq of the transaction and requested a halt and suspension of trading in its shares, with delisting from Nasdaq and deregistration under Section 12(b) of the Exchange Act to follow, along with intended filing of Form 15 to suspend reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-07-15
The Company announces termination of its ADR program and mandatory cancellation of ADSs, with Class A ordinary shares to trade directly on Nasdaq under a new symbol "QH" effective July 17, 2026. While this is a shareholder-approved listing transition rather than a delisting per se, it represents a material change in the trading venue and security structure (share consolidation at 32,000:1 ratio) that affects how existing ADS holders will hold and trade the underlying shares. The mandatory conversion and consolidation constitute a material restructuring of the equity security and its trading mechanism.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-15
Item 8.01
The filing discloses a Nasdaq minimum bid price compliance issue under Listing Rule 5550(a)(2), which is a delisting risk event. Although the Company ultimately regained compliance by July 10, 2026, the disclosure centers on the notice of non-compliance received on January 29, 2026, and the subsequent resolution. This is a material event affecting continued listing status and would be of significant concern to investors, even though the immediate delisting threat has been resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-15
Item 7.01
LQR House Inc. implemented a 1-for-100 reverse stock split effective July 13, 2026, to regain compliance with Nasdaq's $1.00 minimum closing price requirement for continued listing. The company disclosed this delisting-risk mitigation measure via press release on July 15, 2026.
View raw filing on EDGAR →